AVTX Avalo Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1534120 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-77.1%
TTM net income YoY-11.4%
TTM EPS YoY81.6%
Revenue 3-yr CAGR-56.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-15,536.1%
Net margin-7,965.8%
FCF margin-11,123.8%
EBITDA margin-15,497.7%
Returns
ROE-50.1%
ROA-40.9%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets11.7%
Debt / equity0.00x
Current ratio19.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.40x
Accruals ratio16.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $59,000 | $441,000 | $1.92M | $18.05M | $5.40M |
| Cost of revenue | — | — | $1.28M | $3.43M | $1.49M |
| Gross profit | — | — | $640,000 | $14.62M | $3.91M |
| R&D expense | $50.08M | $24.44M | $13.78M | $31.31M | $59.84M |
| SG&A expense | $22.90M | $17.24M | $10.30M | $20.71M | $24.66M |
| Operating income | -$72.92M | -$68.51M | -$27.35M | -$37.44M | -$82.13M |
| Pretax income | -$78.09M | -$35.02M | -$31.53M | -$41.63M | — |
| Income tax | $165,000 | $114,000 | $14,000 | $28,000 | -$196,000 |
| Net income | -$78.26M | -$35.13M | -$31.54M | -$41.66M | -$84.38M |
| EBITDA | -$72.58M | -$68.34M | -$27.19M | -$37.27M | -$80.48M |
| EPS (basic) | -5.84 | -7.94 | -113.58 | -1,063.00 | — |
| EPS (diluted) | -5.84 | -20.91 | -113.58 | -1,063.00 | — |
| Weighted avg. shares (diluted) | 13.40M | 7.50M | 277,727 | 39,202 | — |
| Balance sheet | |||||
| Cash & equivalents | $15.86M | $134.70M | $7.55M | $13.32M | $54.86M |
| Short-term investments | $82.48M | $0 | — | — | — |
| Receivables | — | — | — | $0 | — |
| Inventory | — | — | $0 | $20,000 | $38,000 |
| Current assets | $105.29M | $138.89M | $8.39M | $16.42M | $61.84M |
| Goodwill | $10.50M | $10.50M | $10.50M | $14.41M | $14.41M |
| Intangibles | — | — | — | $0 | $38,000 |
| Total assets | $116.46M | $150.73M | $20.99M | $33.37M | $80.21M |
| Current liabilities | $12.94M | $6.96M | $4.62M | $22.11M | $19.89M |
| Total liabilities | $33.41M | $17.70M | $13.69M | $44.28M | $57.13M |
| Shareholders' equity | $83.05M | $133.03M | $7.30M | -$10.91M | $23.08M |
| Shares outstanding | 18.51M | 10.47M | 801,746 | 39,294 | 9.40M |
| Cash flow statement | |||||
| Operating cash flow | -$51.46M | -$49.06M | -$30.68M | -$26.75M | -$70.89M |
| Capital expenditure | — | $0 | $158,000 | $0 | $113,000 |
| Free cash flow | — | -$49.06M | -$30.84M | -$26.75M | -$71.00M |
| Investing cash flow | -$81.72M | $356,000 | -$133,000 | -$95,000 | -$113,000 |
| Financing cash flow | $14.59M | $175.85M | $25.04M | -$14.70M | $106.76M |
| Depreciation & amortization | $344,000 | $169,000 | $158,000 | $166,000 | $1.66M |
| Stock-based compensation | $13.62M | $5.85M | $3.48M | $7.55M | $8.17M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.